6
total announcements
526445.BO · 15 min delayed
Indrayani Biotech Ltd
Indrayani Biotech Ltd has published its audited financial results for the quarter and year ended March 31, 2026, in accordance with Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Indrayani Biotech Ltd
Indrayani Biotech Ltd has announced its audited financial results for the quarter and year ended March 31, 2026, along with the report of the statutory auditors. The auditors have issued a qualified opinion due to certain matters, including unconfirmed trade creditor balances and non-compliance with Indian Accounting Standards (IND AS) for certain subsidiaries.
Indrayani Biotech Ltd
Indrayani Biotech Ltd has announced its audited standalone and consolidated financial results for the quarter and year ended 31st March 2026. The results have been approved by the Board of Directors, but the consolidated figures have not been subjected to audit/review. The auditor's report includes a qualified opinion due to certain issues with trade creditors and subsidiaries.
Indrayani Biotech Ltd
Indrayani Biotech Ltd has announced its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, along with the auditor's report. The results will be published in newspapers and will also be available on the company's website and the BSE website.
Indrayani Biotech Ltd
Indrayani Biotech Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 17/08/2026 to consider and approve audited financial statements for the Quarter and Financial Year ended March 31, 2026, along with notes thereon and to authorise directors to sign the same.
Indrayani Biotech Ltd
Indrayani Biotech Ltd has announced the indefinite postponement of its partly paid-up Rights Issue. The Rights Issue Committee, at its meeting on June 22, 2026, decided to defer the schedule until further notice, which was previously extended to close on July 24, 2026. While the revised opening and closing dates will be intimated later, the offer price and rights entitlement ratio approved earlier will remain unchanged.